Gabriela Tomescu
Corporate Officer/Principal bei Apneon, Inc.
Profil
Gabriela Tomescu is currently working as the Director of Intellectual Property at Apneon, Inc. She has an undergraduate and graduate degree from The Trustees of Columbia University in The City of New York, an undergraduate degree from The Ohio State University, and a graduate degree from Georgetown University.
Aktive Positionen von Gabriela Tomescu
Unternehmen | Position | Beginn |
---|---|---|
Apneon, Inc.
Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Corporate Officer/Principal | 01.09.2005 |
Ausbildung von Gabriela Tomescu
The Ohio State University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Georgetown University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Apneon, Inc.
Apneon, Inc. Medical SpecialtiesHealth Technology Founded in 2003 by Dr. Lionel Nelson and Eric Doelling, Apneon is dedicated to developing innovative solutions for treating obstructive sleep apnea (OSA) - the cessation of breathing during sleep. OSA is a serious and life-threatening condition that plagues millions of Americans and is most commonly recognized by excessive daytime sleepiness. Even with current treatments, sleep apnea is associated with significantly increased risk of stroke and death. Current treatment methods tend to be poorly tolerated, and/or of limited efficacy. Apneon is developing a unique and inventive approach intended to provide an effective treatment for OSA. | Health Technology |